- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
DNA methyltransferase 3 alpha (DNMT3A) is a nuclear enzyme responsible for establishing de novo DNA methylation patterns during development and cellular differentiation. DNMT3A Antibody / De Novo DNA Methylation Enzyme Antibody is designed to detect this key epigenetic regulator in biological systems where chromatin modification and gene expression control are of interest. DNMT3A catalyzes the transfer of methyl groups to cytosine residues within CpG dinucleotides, creating new methylation marks that shape transcriptional programs. This antibody is part of a collection of Human Protein Microarray validated antibodies that have been screened for specificity across thousands of proteins.
DNMT3A antibody, also referred to as DNA methyltransferase 3 alpha antibody in the literature, recognizes a protein localized predominantly in the nucleus, where it participates in chromatin remodeling and transcriptional regulation. DNMT3A functions in concert with DNMT3B and regulatory cofactors to establish methylation patterns during embryogenesis and maintain cell lineage identity. Unlike DNMT1, which preserves existing methylation, DNMT3A is responsible for generating new methylation marks that influence long-term gene silencing.
This DNMT3A Antibody / De Novo DNA Methylation Enzyme Antibody is uniquely positioned for studies of epigenetic programming and developmental biology. DNMT3A plays a critical role in stem cell differentiation, hematopoiesis, and tissue-specific gene regulation. In immunohistochemistry, DNMT3A is typically observed as nuclear staining in proliferating and differentiating cells, reflecting its role in establishing epigenetic states.
Alterations in DNMT3A expression and function are strongly associated with cancer and hematologic malignancies, particularly acute myeloid leukemia, where DNMT3A mutations are among the most frequently observed epigenetic alterations. Dysregulation of DNMT3A activity leads to aberrant DNA methylation patterns and disrupted gene expression, contributing to tumor development and progression. Detection of DNMT3A expression therefore supports investigation of epigenetic dysregulation in disease contexts.
The mouse monoclonal clone PCRP-DNMT3A-1E2 provides reliable detection of DNMT3A, supported by protein microarray specificity validation data demonstrating selective binding to the intended target. This DNMT3A Antibody / De Novo DNA Methylation Enzyme Antibody is suitable for detecting DNMT3A expression in research applications including western blot, immunohistochemistry, and other studies of epigenetic regulation. Its performance supports detailed evaluation of DNMT3A localization and function across diverse biological systems.
This antibody supports investigation of de novo DNA methylation, epigenetic programming, and disease-associated changes in DNMT3A expression. It is part of a broader DNA Methylation antibody panel offered by NSJ Bioreagents.
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the DNMT3A Antibody / De Novo DNA Methylation Enzyme Antibody to be titered up or down for optimal performance.
Recombinant full length human protein was used as the immunogen for this DNMT3A antibody.
Store the DNMT3A antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
DNMT3A antibody, DNA methyltransferase 3 alpha antibody, DNMT3A protein antibody, De novo methyltransferase antibody, Epigenetic methylation enzyme antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.